More than 50,000 doses of SKY-0515 have now been administered to patients. BOSTON, Nov. 5, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced that the first U.S....